Specify a stock or a cryptocurrency in the search bar to get a summary
Siegfried Holding Ltd
SGFEFSiegfried Holding AG, together with its subsidiaries, provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide. It offers pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale-up and clinical trial material production services. The company develops and produces APIs and intermediates, as well as finished dosage forms, including solid oral dosage forms, sterile and aseptic filling injectables, ophthalmics, and inhalative products. In addition, it provides APIs and controlled substances focusing on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition; exclusive synthesis services comprising process and chemical development, analytical development, pilot manufacturing and scale-up, and commercial manufacturing; and viral vector manufacturing solutions. Further, the company licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for products. Siegfried Holding AG was founded in 1873 and is headquartered in Zofingen, Switzerland. Address: Untere Bruehlstrasse 4, Zofingen, Switzerland, 4800
Analytics
WallStreet Target Price
872.61 CHFP/E ratio
39.3277Dividend Yield
0.31 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SGFEF
Dividend Analytics SGFEF
Dividend growth over 5 years
42 %Continuous growth
9 yearsPayout Ratio 5 years average
15 %Dividend History SGFEF
Stock Valuation SGFEF
Financials SGFEF
Results | 2019 | Dynamics |